Oncolytics Biotech Inc.

08:41 AM EST - Oncolytics Biotech Inc. : Announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Results from the bridging trial are expected to allow Adlai Nortye to include data from Oncolytics' North American metastatic breast cancer trials in a future submission to Chinese regulators. The first of Oncolytics' randomized phase 2 trials, IND-213, showed that treatment with pelareorep and paclitaxel led to a statistically significant increase in overall survival compared to treatment with paclitaxel alone. Oncolytics' second randomized phase 2 trial, BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor. Oncolytics Biotech Inc. shares T.ONC are trading unchanged at $2.65.

Stocks in Play